Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia Gravis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Generalized myasthenia gravis will develop in more than 50% of patients who present with ocular myasthenia gravis, typically within 2 years. The optimal treatment of ocular myasthenia gravis, including the use of corticosteroids, remains controversial. In addition, the prevalence of thymoma and the optimal performance of the edrophonium chloride test for ocular myasthenia remain unknown. OBJECTIVE: To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis. METHODS: We reviewed an ocular myasthenia gravis database of 147 patients. Patients underwent measurement of acetylcholine receptor (AChR) antibody levels and chest computed tomography. Unless contraindicated, patients with diplopia were recommended for therapy with prednisone, up to 40 to 60 mg/d, with the dosage tapered for 5 to 6 weeks. Most continued to receive daily or alternate-day doses of 2.5 to 10 mg to prevent diplopia. Patients not given prednisone (untreated group) received pyridostigmine bromide or no medication. After the diagnosis, we documented the signs and symptoms of ocular and generalized myasthenia gravis and performed 2-year follow-up in 94 patients. RESULTS: The mean dose of edrophonium chloride to give a positive response was 3.3 mg (SD, 1.6 mg) for ptosis and 2.6 mg (SD, 1.1 mg) for ocular motor dysfunction. Thymoma occurred in 1 patient (0.7%). Generalized myasthenia gravis developed within 2 years in 4 of 58 treated and 13 of 36 untreated patients. The odds ratio (OR) for development of generalized disease in the treated group was 0.13 (95% confidence interval [CI], 0.04-0.45) compared with the untreated group. The AChR antibody level was not predictive of development of generalized myasthenia gravis at 2 years, but the risk was greater in patients with abnormal AChR antibody levels (OR, 6.33; 95% CI, 1.71-23.42). Logistic regression that included age, abnormal AChR antibody level, and prednisone therapy yielded significance only for abnormal AChR antibody level (OR, 7.03; 95% CI, 1.35-36.64) and treatment (OR, 0.06; 95% CI, 0.01-0.30). CONCLUSIONS: At 2 years, prednisone treatment appears to reduce the incidence of generalized myasthenia gravis to 7% in contrast to 36% of patients who did not receive prednisone. Thymoma, although uncommon, occurs in ocular myasthenia gravis. Only small amounts of edrophonium are needed to diagnose ocular myasthenia gravis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biostatistics: A Methodology for the Health Sciences.
D'Agostino, R. B., Fisher, L. D., & van Belle, G. (1995) · Journal of the American Statistical Association · doi:10.2307/2291095 · Cited by 957
Binocular Vision and Ocular Motility: Theory and Management of Strabismus
(1986) · Archives of Ophthalmology · doi:10.1001/archopht.1986.01050190041032 · Cited by 891
Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients
Pascuzzi, R. M., Coslett, H. B., & Johns, T. R. (1984) · Annals of Neurology · doi:10.1002/ana.410150316 · Cited by 333
The natural course of myasthenia gravis: a long term follow up study.
Oosterhuis, H. J. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.10.1121 · Cited by 326
Spiera, R., Mitnick, H. J., Kupersmith, M. J., Richmond, M., Spiera, H., Peterson, M. G. E., & Paget, S. A. (2001) · PubMed · Cited by 248
Self-citationThe efficacy and safety of low-dose corticosteroids for rheumatoid arthritis
Caldwell, J. R., & Fürst, D. E. (1991) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(91)90051-z · Cited by 115
Treatment of Ocular Myasthenia With Corticosteroids
Agius, M. A. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.750 · Cited by 36
Hatz, H. J., & Helmke, K. (1992) · PubMed · Cited by 13
Cited by
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Metadata
- Authors
- Kupersmith, M. J., Latkany, R., & Homel, P.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-02-01
- Volume
- 60
- Issue
- 2
- Pages
- 243
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2035289940
- Cited by
- 253
- References
- 8
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia Gravis. https://app.cochat.ai/papers/10.1001/archneur.60.2.243
- The paper
- Kupersmith, M. J., Latkany, R., & Homel, P. (2003). Development of Generalized Disease at 2 Years in Patients With Ocular Myasthenia Gravis. Archives of Neurology. https://doi.org/10.1001/archneur.60.2.243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.